{"classes":[{"categories":[{"measurements":[{"comment":"Due to smaller number of participants with an event, 95% CI could not be calculated.","groupId":"OG000","lowerLimit":"8.542","upperLimit":"NA","value":"11.07"},{"comment":"Due to smaller number of participants with an event, 95% CI could not be calculated.","groupId":"OG001","lowerLimit":"10.612","upperLimit":"NA","value":"13.27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"93"}],"units":"Participants"}],"description":"DOR:time from date of first IRC determined response(PR or better) to date of first IRC-PD or death, whichever occurred first.DOR was determined only for participants who had achieved a response of PR or better based on disease assessment by IRC.If progression or death was not observed,participant was censored at date of participants last progression-free tumor assessment prior to initiation of further anti-myeloma treatment(if any)and study cut-off date. PD(IMWG criteria):increase of \\>=25% from lowest confirmed value in any one of following criteria: serum M-protein (absolute increase must be \\>=0.5 g/dL), serum M-protein increase \\>=1g/dL if lowest M component was \\>=5g/dL;urine M-component (absolute increase must be \\>=200mg/24 hour),appearance of new lesion(s), \\>=50% increase from nadir in SPD of \\>1 lesion,or \\>=50% increase in the longest diameter of a previous lesion \\>1 cm in short axis. PR:\\>=50% reduction of serum M-protein and reduction in 24h urinary M-protein by \\>=90%/\\<200mg/24h.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 73.7 weeks).","id":"OG000","title":"Pd (Pomalidomide + Dexamethasone)"},{"description":"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).","id":"OG001","title":"IPd (Isatuximab + Pomalidomide + Dexamethasone)"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on responders in ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From the date of the first IRC determined response to the date of first IRC progression or death, whichever occurred first (maximum duration 76.7 weeks)","title":"Duration of Response (DOR) as Per Independent Response Committee","type":"SECONDARY","unitOfMeasure":"months"}